Koichi Node


Ontology type: schema:Person     


Person Info

NAME

Koichi

SURNAME

Node

Publications in SciGraph latest 50 shown

  • 2022-11-15 Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial in HYPERTENSION RESEARCH
  • 2022-10-12 Correction to: Current clinical use of intravascular ultrasound imaging to guide percutaneous coronary interventions (update) in CARDIOVASCULAR INTERVENTION AND THERAPEUTICS
  • 2022-09-19 Current clinical use of intravascular ultrasound imaging to guide percutaneous coronary interventions (update) in CARDIOVASCULAR INTERVENTION AND THERAPEUTICS
  • 2022-09-13 Pathogenic connection between hypertension and type 2 diabetes: how do they mutually affect each other? in HYPERTENSION RESEARCH
  • 2022-09-06 Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists in CARDIOVASCULAR DIABETOLOGY
  • 2022-08-10 Predictive value of neutrophil-to-lymphocyte ratio for the fatality of COVID-19 patients complicated with cardiovascular diseases and/or risk factors in SCIENTIFIC REPORTS
  • 2022-08-08 Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial in CARDIOVASCULAR DIABETOLOGY
  • 2022-08-08 Involvement of the PI3K/AKT Pathway in the Formation and Fusion of Spheroids Derived from Human Dermal Fibroblast for Tissue Engineering Technology in CELL AND TISSUE BIOLOGY
  • 2022-07-05 Update on Hypertension Research in 2021 in HYPERTENSION RESEARCH
  • 2022-06-22 Body fluid regulation via chronic inhibition of sodium–glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial in CLINICAL RESEARCH IN CARDIOLOGY
  • 2022-06-10 Prevalence of hypertensive diseases and treated hypertensive patients in Japan: A nationwide administrative claims database study in HYPERTENSION RESEARCH
  • 2022-05-18 Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus in CARDIOVASCULAR DIABETOLOGY
  • 2022-05-11 Author Correction: A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction in SCIENTIFIC REPORTS
  • 2022-04-28 A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction in SCIENTIFIC REPORTS
  • 2022-03-03 Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives in CARDIOVASCULAR INTERVENTION AND THERAPEUTICS
  • 2022-02-15 Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study in HYPERTENSION RESEARCH
  • 2021-12-27 Better vascular function tests in cardiovascular care: learning from evidence and providing improved diagnostics to the patient in HYPERTENSION RESEARCH
  • 2021-12-02 Spatiotemporal dynamics of SETD5-containing NCoR–HDAC3 complex determines enhancer activation for adipogenesis in NATURE COMMUNICATIONS
  • 2021-10-17 Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study in HYPERTENSION RESEARCH
  • 2021-10-15 Annual reports on hypertension research 2020 in HYPERTENSION RESEARCH
  • 2021-10-01 Cardiac acoustic biomarkers as surrogate markers to diagnose the phenotypes of pulmonary hypertension: an exploratory study in HEART AND VESSELS
  • 2021-09-14 Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial in CARDIOVASCULAR DIABETOLOGY
  • 2021-09-03 Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents in CARDIOVASCULAR DIABETOLOGY
  • 2021-08-11 Clinical roles of vascular function assessment in cancer care in SUPPORTIVE CARE IN CANCER
  • 2021-07-31 Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin in CARDIOVASCULAR DIABETOLOGY
  • 2021-06-28 Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial in CARDIOVASCULAR DIABETOLOGY
  • 2021-05-14 Hypertension in diabetes care: emerging roles of recent hypoglycemic agents in HYPERTENSION RESEARCH
  • 2021-05-05 The lncRNA Caren antagonizes heart failure by inactivating DNA damage response and activating mitochondrial biogenesis in NATURE COMMUNICATIONS
  • 2021-03-06 Advance care planning from the penultimate hospitalization in patients with end-stage heart failure: a single-center, 10-year experience in HEART AND VESSELS
  • 2021-02-11 Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors in CARDIOVASCULAR DIABETOLOGY
  • 2020-12-07 How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition? in CARDIOVASCULAR DIABETOLOGY
  • 2020-11-30 Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society in DIABETOLOGY INTERNATIONAL
  • 2020-10-12 Reduction in hsCRP levels is associated with decreased incidence of cardiovascular events in Japanese hypertensive women but not in men in SCIENTIFIC REPORTS
  • 2020-09-23 Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design in DIABETES THERAPY
  • 2020-09-03 Vascular functional tests and preemptive medicine in HYPERTENSION RESEARCH
  • 2020-09-02 Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care in CARDIOVASCULAR DIABETOLOGY
  • 2020-06-15 Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy in CARDIOVASCULAR DIABETOLOGY
  • 2020-06-13 Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial in CARDIOVASCULAR DIABETOLOGY
  • 2020-06-11 Promising roles of sodium–glucose cotransporter 2 inhibitors in heart failure prevention and treatment in DIABETOLOGY INTERNATIONAL
  • 2020-05-26 Usefulness of the SAGE score to predict elevated values of brachial-ankle pulse wave velocity in Japanese subjects with hypertension in HYPERTENSION RESEARCH
  • 2020-05-14 Bright light improves sleep in patients with Parkinson’s disease: possible role of circadian restoration in SCIENTIFIC REPORTS
  • 2020-05-12 Does cilnidipine, a dual L- and N-type Ca2+ blocker, shows promise in drug repositioning approaches? in HYPERTENSION RESEARCH
  • 2020-03-09 Increased arterial stiffness and cardiovascular risk prediction in controlled hypertensive patients with coronary artery disease: post hoc analysis of FMD-J (Flow-mediated Dilation Japan) Study A in HYPERTENSION RESEARCH
  • 2020-02-21 Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial in SCIENTIFIC REPORTS
  • 2020-01-16 Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia in CEN CASE REPORTS
  • 2020-01-10 Effect of rivaroxaban on urinary albumin excretion in patients with atrial fibrillation and chronic kidney disease: a randomized trial (X-NOAC) in HYPERTENSION RESEARCH
  • 2019-11-28 GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy in CARDIOVASCULAR DIABETOLOGY
  • 2019-11-16 Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial in CARDIOVASCULAR DIABETOLOGY
  • 2019-11-12 Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial in SCIENTIFIC REPORTS
  • 2019-08-06 Publisher Correction: Development of an immunodeficient pig model allowing long-term accommodation of artificial human vascular tubes in NATURE COMMUNICATIONS
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.412339.e", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.26091.3c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419943.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.26999.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.136593.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5802.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410785.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.62560.37", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7597.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.470737.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410714.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416985.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.255137.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.415774.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5570.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.240341.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.38142.3c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.258333.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.415500.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412039.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416518.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.265061.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410796.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10253.35", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.440125.6", 
            "type": "Organization"
          }
        ], 
        "familyName": "Node", 
        "givenName": "Koichi", 
        "id": "sg:person.01100453460.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100453460.13"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-12-01T07:12", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/person/person_625.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01100453460.13'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01100453460.13'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01100453460.13'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01100453460.13'


     

    This table displays all metadata directly associated to this object as RDF triples.

    64 TRIPLES      10 PREDICATES      35 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01100453460.13 schema:affiliation Ne94aed8a524f4316b8deefca91c7cb42
    2 grid-institutes:grid.10253.35
    3 grid-institutes:grid.136593.b
    4 grid-institutes:grid.240341.0
    5 grid-institutes:grid.255137.7
    6 grid-institutes:grid.258333.c
    7 grid-institutes:grid.26091.3c
    8 grid-institutes:grid.265061.6
    9 grid-institutes:grid.26999.3d
    10 grid-institutes:grid.38142.3c
    11 grid-institutes:grid.410714.7
    12 grid-institutes:grid.410785.f
    13 grid-institutes:grid.410796.d
    14 grid-institutes:grid.412039.d
    15 grid-institutes:grid.415500.5
    16 grid-institutes:grid.415774.4
    17 grid-institutes:grid.416518.f
    18 grid-institutes:grid.416985.7
    19 grid-institutes:grid.419943.2
    20 grid-institutes:grid.440125.6
    21 grid-institutes:grid.470737.0
    22 grid-institutes:grid.5570.7
    23 grid-institutes:grid.5802.f
    24 grid-institutes:grid.62560.37
    25 grid-institutes:grid.7597.c
    26 schema:familyName Node
    27 schema:givenName Koichi
    28 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100453460.13
    29 schema:sdDatePublished 2022-12-01T07:12
    30 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    31 schema:sdPublisher N4374dd119f1a43cebe1ae945585f3ef8
    32 sgo:license sg:explorer/license/
    33 sgo:sdDataset persons
    34 rdf:type schema:Person
    35 N4374dd119f1a43cebe1ae945585f3ef8 schema:name Springer Nature - SN SciGraph project
    36 rdf:type schema:Organization
    37 Ne94aed8a524f4316b8deefca91c7cb42 schema:affiliation grid-institutes:grid.412339.e
    38 sgo:isCurrent true
    39 rdf:type schema:OrganizationRole
    40 grid-institutes:grid.10253.35 schema:Organization
    41 grid-institutes:grid.136593.b schema:Organization
    42 grid-institutes:grid.240341.0 schema:Organization
    43 grid-institutes:grid.255137.7 schema:Organization
    44 grid-institutes:grid.258333.c schema:Organization
    45 grid-institutes:grid.26091.3c schema:Organization
    46 grid-institutes:grid.265061.6 schema:Organization
    47 grid-institutes:grid.26999.3d schema:Organization
    48 grid-institutes:grid.38142.3c schema:Organization
    49 grid-institutes:grid.410714.7 schema:Organization
    50 grid-institutes:grid.410785.f schema:Organization
    51 grid-institutes:grid.410796.d schema:Organization
    52 grid-institutes:grid.412039.d schema:Organization
    53 grid-institutes:grid.412339.e schema:Organization
    54 grid-institutes:grid.415500.5 schema:Organization
    55 grid-institutes:grid.415774.4 schema:Organization
    56 grid-institutes:grid.416518.f schema:Organization
    57 grid-institutes:grid.416985.7 schema:Organization
    58 grid-institutes:grid.419943.2 schema:Organization
    59 grid-institutes:grid.440125.6 schema:Organization
    60 grid-institutes:grid.470737.0 schema:Organization
    61 grid-institutes:grid.5570.7 schema:Organization
    62 grid-institutes:grid.5802.f schema:Organization
    63 grid-institutes:grid.62560.37 schema:Organization
    64 grid-institutes:grid.7597.c schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...